Hi Grey_Ghost, could you please share last week's count?

Hey dd, any word from your contacts? What do you think happens if July comes and goes without any news?

How long can someone keep denying what’s right in front of them? At the end of the day, people have invested their money, and most of us strongly believe deeply in the science and innovation behind it. It’s hard to accept that something this promising could be turned down by the MHRA. But this silence is tough, especially for those of us (myself included) who may have invested more than we should have.
If management could just confirm that there’s no regulatory hold or issue, most of us would be willing to wait another two or three months. The real challenge is sitting here in complete uncertainty, with no communication and no direction.

Jesster, I agree with everything you said - but it’s honestly quite concerning.
June is almost over, and many of us were hoping July would be the month MHRA makes a decision. Yet the company remains silent. Defenders of management say they were upfront from the beginning - that no updates would be given until MHRA decides. But seriously, who thought it would drag on this long? There's only so much patience people can have.

Personally, I’ve tried to piece things together myself, just to get a sense of what’s happening with both the company and MHRA. And here’s why I think my guess might hold some weight:

NHS likely communicated with MHRA before they updated their list - that wouldn't happen in isolation.
If management knew the application had already been referred to the CHM, wouldn't they be issuing more shares to raise cash, similar to previous months? But this month’s dilution is unusually low.
That doesn’t guarantee anything, of course, but it does raise some questions worth thinking about.

Markets will close on Thursday for the Juneteenth holiday. Both stock and bond markets will close Thursday.

From ChatGPT:
✅ Personalized Cancer Vaccines Under MHRA Review
DCVax-L (Northwest Biotherapeutics)
This vaccine targets glioblastoma multiforme (GBM) and has been under compassionate use in the UK for over four years. The MHRA received its Marketing Authorisation Application (MAA) in December 2023, with a decision expected imminently. The vaccine has demonstrated a favorable safety profile and significant survival benefits in clinical trials.
TG4050 (Transgene)
Designed using the myvac™ platform, TG4050 is an individualized immunotherapy targeting HPV-negative head and neck cancers. The MHRA has approved a Phase 1 clinical trial in the UK, which is set to commence soon. This trial will assess the vaccine's safety and ability to stimulate an immune response.
OVM-200 (Oxford Vacmedix)
This vaccine targets survivin, a protein overexpressed in various cancers. The MHRA has approved a Phase 1 trial in patients with non-small cell lung cancer, prostate cancer, and ovarian cancer. The trial aims to evaluate the vaccine's safety and its ability to provoke an immune response.
ITOP1 (Infinitopes)
ITOP1 is an 'off-the-shelf' precision cancer vaccine targeting oesophageal adenocarcinoma. The MHRA has granted approval for a Phase I/IIa clinical trial, which is scheduled to begin in Q2 2025. The trial will assess the vaccine's safety and effectiveness in preventing cancer recurrence.

Why do you think it’ll be late 2025 or early 2026? I’m not convinced.

Hi TVOP,
Hope you’re doing well and still keeping an eye on these messages. When you have a moment, could you chime in and help clarify the statement below?
Do you know if there are any other personalized cancer vaccines currently seeking approval from the MHRA?

mani, I’m not sure if there are any other

check this:
All clinical trial approval backlogs are cleared, and performance targets are now being met.

Glad you clarified, Gary. The tone shift caught my eye — yesterday's message felt a bit more bullish. Yesterday you were confidently eyeing new 52-week highs, and now you’re acting like you were just stating facts. That’s a pretty quick backpedal.

Honestly, the reduced dilution this month is the best news so far this year. Based on their latest balance sheet, they don’t have much cash flow and likely need to continue diluting to stay operational. But the slowdown suggests they’re not in a rush. It could mean they’re waiting for positive news to hit and the stock to rise before issuing more shares. Just my take — not trying to pump anything.

Gary, could you please review your post again?

June’s wrapping up in two weeks, July will roll in with the same script, and at this point, delays don’t even faze us anymore. Oh boy!

No need to worry about us — you’re already on the Nothing-Burger diet daily!

No approval news this morning, and the silence continues. Let’s wait for the presentation to see if they announce anything new. The stock needs fresh news and excitement to drive volume and create momentum. Without that, it will likely continue trading in the same pattern until the approval news is released.

It could be anything, but I’m more inclined to believe that something positive may be on the horizon, otherwise, why the reduced dilution? In a worst-case scenario, if DCVax approval moves into a CHMP review, they might have to start direct trials and continue diluting as before. I could be wrong, but this line of thinking makes sense to me.
And why send out an email and press release about the New York conference? It’s hard not to overthink it—this stuff gets pretty nerve-wracking.

In my opinion, releasing a press release is more important at this stage than updating the website. This PR doesn’t come across as a pump, and as I mentioned below, the reduced dilution suggests they’re anticipating approval soon. Fingers crossed for next week.

Gary, could you please keep your messages more concise? To be honest, constantly reading speculative scenarios and price projections in nearly every post gets a bit tiring. Let’s wait for the approval first—then we can dive into the future potential. I do respect your knowledge and experience, but the repetition makes it hard to stay engaged.🙏

I've only known about this company last 10 years, so I'm not familiar with its early history or when it initially went public over 20 years ago. When I first bought the stock, it was trading around $0.44 on the OTC market.

I asked ChatGPT when NWBO went public, and it provided the information below. Can you confirm if it's accurate?

* Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) went public on December 14, 2001, through an initial public offering (IPO) that raised $20 million by pricing 4 million shares at $5 each. The company's stock began trading on the Nasdaq National Market under the ticker symbol NWBT.

* In 2012, the company transitioned its listing to the Nasdaq Capital Market, where it continues to trade under the ticker NWBO.

The presentation will take place on Monday, June 16, at 2:50 p.m. The slides will be posted on the Company's website after the presentation.

The relative reduction in dilution this month is a positive indicator. Could it be a sign that approval is on the horizon, perhaps even this month?

Gary, I agree that name-calling and using inappropriate language in public forums is not acceptable. However, I’m struggling to find the rationale in your recent posts. It's been around one year six months since the company submitted for approval. You've been suggesting since February 2024 that approval could come at any time, and now we're in June 2025—with no approval and the stock sitting at $0.26. Your recent messages feel overly optimistic and are becoming frustrating to some, especially given the lack of tangible progress.

Patience is key right now—there's no point in getting discouraged at this stage. We've already waited this long, and with each passing day, we're getting closer. Some of you even anticipated that approval might come by July. Who knows? Something positive could happen next week, maybe during or right after the conference.

It's likely that they're not paying for a dedicated web developer to maintain the website. A part-time employee could probably handle the task over a weekend. Right now, their focus seems to be on the MHRA process, and the company may not want to allocate funds toward web development at this stage.

+ Dilution has been relatively low over the past twenty days.

06/09/2025 1,452,769,971 (+1,000,000 = 126,863,005 YTD)
06/06/2025 1,451,769,971 (+412,632 = 125,863,005 YTD)
06/05/2025 1,451,357,339 (+674,158 = 125,450,373 YTD)
06/02/2025 1,450,683,181 (+720,875 = 124,776,215 YTD)
05/29/2025 1,449,962,306 (+1,622,544 = 124,055,340 YTD)
05/28/2025 1,448,339,762 (+1,568,271 = 122,432,796 YTD)
05/23/2025 1,446,771,491 (+1,009,033 = 120,864,525 YTD)
05/22/2025 1,445,762,458 (+608,082 = 119,855,492 YTD)

Regardless of how the stock price reacts to the company’s press release, it was encouraging to finally see an email from Northwest after such a long silence. I remain hopeful that we’ll receive the approval email or PR from NW very soon.

The broader stock markets had declined by 35% but recovered within two months. Had the MHRA approval come during that window, it could have been a golden opportunity for us to diversify some of our funds into other stocks.

Safe travels, Gary! Not sure when you'll make it back to New York again, but hopefully the MHRA decision comes while you're there this time rather than another 6 to 12 months down the line. I don’t have your level of patience to wait that long!

We vent our frustration but toward whom? Toward those who are still hopeful and patiently waiting? Management isn’t listening, so what’s the point? Sometimes staying quiet is the better choice.

The stock has dropped back to the $0.25 range, and today’s volume looks slightly higher than the last couple of days—possibly due to dilution. Hopefully, the worst is behind us, and some long-awaited good news is just around the corner.

In my opinion, management seems to be in a really tough spot. They're stuck waiting on the MHRA and can’t take any meaningful action until a decision is made. In the meantime, they’ve had to raise funds just to keep operations running and the lights on. Forget about ASM for now.

I’m just as frustrated as you and probably everyone else here because none of us knows how much longer this wait will last.

With colleges opening in August 2025, I have some payments coming up, and honestly, I regret not selling a bit when the stock ticked up in April.

I haven't seen the following posters in a while—are they still active on this hub, or have they moved on?
dbing | TVOP | Newman2021, etc

Attila, here are my thoughts:
1. If Northwest had attended ASCO, investors would likely have questioned them about the delay in receiving approval, given that it's been over a year and half since submission. That would have put them in a very uncomfortable position. Attending the NYAS conference instead is a much easier path—they can present when their slot comes up without having to defend themselves or face awkward questions about the delay.

2. While this is just speculation, the choice of NYAS over ASCO might indicate that management was hopeful about receiving approval before the NYAS event—possibly due to confidence following their response to the latest RFI. A presentation after approval would certainly carry more weight and be far more effective.

That said, it's honestly difficult to tell where exactly things are stuck and when this quiet period will finally end.

When do you think this wait will finally come to an end? Do you believe it will be resolved by year’s end, regardless of whether approval is granted? Today is the last working day of May — that leaves June, July, August, September, October, November, and December.

Hi Lykiri, I’ve gone through all the updates on his GoFundMe page. It appears he’s received several different treatments beyond just DCVax-L, but the information is somewhat unclear and a bit difficult to follow. If you’re able to contact him through Instagram (I don’t have an account), would you mind asking if he could provide a detailed update outlining all the treatments he’s undergone over the past 18 months?

https://www.gofundme.com/f/glioblastoma-dcvaxl-immunotherapy-vaccine?utm_medium=email&utm_source=product&utm_campaign=p_email_m_pd-5332-donation-receipt-adyen&utm_content=internal

One consistent theme in his updates is his outspoken criticism of the NHS for not offering immunotherapies free of charge to taxpayers..

He appeared on ITV Wales News — here’s the link:
🔗 ITV Wales News Article

Also, I noticed his blog hasn't been updated in a while.
https://matthewcollins5.wordpress.com/2025/02/24/radical-hope/

That's great, Lykiri and thanks for sharing! I've been checking his GoFundMe page whenever I receive an email, and I also made a small donation. How and where did you find the most recent update below (May 27th)? It doesn't appear to be posted on his GoFundMe page.

https://www.gofundme.com/f/glioblastoma-dcvaxl-immunotherapy-vaccine?utm_medium=email&utm_source=product&utm_campaign=p_email_m_pd-5332-donation-receipt-adyen&utm_content=internal
May 27, 2025

if we had certainty that the company is only addressing an RFI and that the approval is not being held up, we would see this as an opportunity to increase our position—especially given the current price, which is significantly discounted in light of a potential approval. In that case, we could wait patiently without frustration. However, the ongoing silence is extremely unsettling. Our funds are completely tied up in this, leaving us unable to invest elsewhere—particularly in promising opportunities like AI stocks.

Attila, have you fully reconsidered your position regarding the possibility that NWBO’s approval may be delayed or withheld by the MHRA?